Now showing items 1-10 of 80
Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial.
BACKGROUND: An urgent need to reduce the metabolic side-effects of glucocorticoid overexposure has been recognised, as glucocorticoid excess can lead to Cushing's syndrome, which is associated with high morbidity. We aimed ...
Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms.
(Oxford University Press, 2020-03-20)
Substantial advances have been made recently in the pathobiology of pituitary tumors. Similar to many other endocrine tumors, over the last few years we have recognized the role of germline and somatic mutations in a number ...
ESE audit on management of adult growth hormone deficiency in clinical practice
Guidelines recommend adults with pituitary disease in whom GH therapy is contemplated, to be tested for GH deficiency (AGHD); however, clinical practice is not uniform. Aims: 1) To record current practice of AGHD management ...
AIPvariant causing familial prolactinoma
Corticotroph aggressive pituitary tumours and carcinomas frequently harbour ATRX mutations.
CONTEXT: Aggressive pituitary tumours (APTs) are characterised by unusually rapid growth and lack of response to standard treatment. About 1-2% develop metastases being classified as pituitary carcinomas (PCs). For unknown ...
Sensitivity and specificity of the macimorelin test for diagnosis of AGHD.
OBJECTIVE: The macimorelin test is approved for the diagnosis of adult growth hormone deficiency (AGHD) based on its efficacy vs the insulin tolerance test (ITT). Macimorelin has a significant advantage over ITT in avoiding ...
Molecular characterization of DICER1-mutated pituitary blastoma.
Pituitary blastoma (PitB) has recently been identified as a rare and potentially lethal pediatric intracranial tumor. All cases that have been studied molecularly possess at least one DICER1 pathogenic variant. Here, we ...
Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?
The WHO Classification of Endocrine Tumours designates pituitary neoplasms as adenomas. A proposed nomenclature change to pituitary neuroendocrine tumors (PitNETs) has been met with concern by some stakeholder groups. The ...